quinupristin-dalfopristin
(PPKJUHVNTMYXOD-GKSTYDNOSA-N)
Structure
- SMILES
- CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)C2N(C(=O)[C@@H](N(C(=O)[C@H]3N(C1=O)CCC3)C)Cc1ccc(cc1)N(C)C)C[C@@H](CS[C@@H]1CN3CCC1CC3)C(=O)C2)c1ccccc1.CCN(CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)Cc1nc(C2=O)co1)O)/C)CC
- Molecular Formula:
- C87H117N13O19S2
- Molecular Weight:
- 1713.070
- Log P:
- 6.7404
- Hydrogen Bond Acceptor:
- 33
- Hydrogen Bond Donor:
- 6
- TPSA:
- 441.3
- CAS Number(s):
- 126602-89-9
Synonym(s)
1.
quinupristin-dalfopristin
2.
RP 59500
3.
RP-59500
4.
Synercid
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Myalgia | FAERS: 3 | US FAERS | |
| 2 | Enterococcal infection | FAERS: 2 | US FAERS | |
| 3 | Infusion Site Extravasation | FAERS: 2 | US FAERS | |
| 4 | Infusion site exfoliation | FAERS: 2 | US FAERS | |
| 5 | Infusion site pain | FAERS: 2 | US FAERS | |
| 6 | Infusion site ulcer | FAERS: 2 | US FAERS | |
| 7 | Infusion site vesicles | FAERS: 2 | US FAERS | |
| 8 | No adverse event | FAERS: 2 | US FAERS | |
| 9 | Wrong technique in drug usage process | FAERS: 2 | US FAERS | |
| 10 | Alanine Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 11 | Arthralgia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Aspartate Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 13 | Asthenia | FAERS: 1 | US FAERS | |
| 14 | Blood alkaline phosphatase increased | FAERS: 1 | US FAERS | |
| 15 | Bronchial secretion retention | FAERS: 1 | US FAERS | |
| 16 | Chest Pain | FAERS: 1 | US FAERS | |
| 17 | Device related infection | FAERS: 1 | US FAERS | |
| 18 | Disease Progression | FAERS: 1 | US FAERS | |
| 19 | Drug Dependence | FAERS: 1 | US FAERS | |
| 20 | Drug administration error | FAERS: 1 | US FAERS | |
| 21 | Drug ineffective | FAERS: 1 | US FAERS | |
| 22 | Drug resistance | FAERS: 1 | US FAERS | |
| 23 | Extravasation | FAERS: 1 | US FAERS | |
| 24 | Gamma-Glutamyltransferase Increased | FAERS: 1 | US FAERS | |
| 25 | General physical health deterioration | FAERS: 1 | US FAERS | |
| 26 | Infusion site reaction | FAERS: 1 | US FAERS | |
| 27 | Joint stiffness | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 28 | Nausea | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 29 | Pain | FAERS: 1 | US FAERS | |
| 30 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 31 | Sepsis | FAERS: 1 | US FAERS | |
| 32 | Vomiting | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.